La survie des enfants nés avant terme s'est améliorée et ceux-ci sont donc plus nombreux ,
des prédispositions multigéniques ainsi que l'environnement respiratoire de l'enfant jouent un rôle essentiel ,
Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease, J Pediatr, 2003. ,
Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia, Pediatr Infect Dis J, 2004. ,
Palivizumab efficacy in preterm infants with gestational age ???30 weeks without bronchopulmonary dysplasia, Pediatric Pulmonology, vol.90, issue.3, 2007. ,
DOI : 10.1002/ppul.20503
Hospitalizations for respiratory syncytial virus bronchiolitis in preterm infants at <33 weeks gestation without bronchopulmonary dysplasia: the CASTOR study, Epidemiology and Infection, vol.31, issue.04, 2013. ,
DOI : 10.1067/mpd.2002.128114
URL : https://hal.archives-ouvertes.fr/hal-01194211
Methodological aspects of economic evaluation in pediatrics: illustration by RSV infection prophylaxis in the French setting. Arch Pédiatrie Organe Off Sociéte Fr Pédiatrie, 2008. ,
Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children, Cochrane Database Syst Rev, 2013. ,
SYNAGIS : recommandations SFN Juillet http://www.reseaupsof.fr/medias/recommandations_synagis, p.5014, 2007. ,
A Systematic Review of Compliance with Palivizumab Administration for RSV Immunoprophylaxis, Journal of Managed Care Pharmacy, vol.16, issue.1, 2010. ,
DOI : 10.18553/jmcp.2010.16.1.46
Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective, International Journal of Pediatrics, vol.26, issue.6, 2014. ,
DOI : 10.1016/S0022-3476(88)80008-8
Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry, Pediatr Pulmonol, 2003. ,
Impact of a targeted educational intervention on respiratory syncytial virus bronchiolitis prevention in full-term and preterm infants. Arch Pédiatrie Organe Off Sociéte Fr Pédiatrie, 2015. ,
FLIP-2 Study, The Pediatric Infectious Disease Journal, vol.27, issue.9, 2008. ,
DOI : 10.1097/INF.0b013e3181710990
Can we improve the targeting of respiratory syncytial virus (RSV) prophylaxis in infants born 32???35 weeks??? gestational age with more informed use of risk factors?, The Journal of Maternal-Fetal & Neonatal Medicine, vol.3, issue.10, 2015. ,
DOI : 10.1136/thoraxjnl-2011-201054c.170
European risk factors' model to predict hospitalization of premature infants born 33???35 weeks' gestational age with respiratory syncytial virus: validation with Italian data, The Journal of Maternal-Fetal & Neonatal Medicine, vol.35, issue.1, 2011. ,
DOI : 10.1542/peds.102.3.531
Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants. Pediatrics, 2013. ,
Short- and Long-term Pulmonary Outcome of Palivizumab in Children Born Extremely Prematurely, Chest, vol.149, issue.3, p.2015 ,
DOI : 10.1378/chest.15-0328
relatif aux médicaments à usage pédiatrique, modifiant le règlement (CEE) no 1768, CE ainsi que le règlement (CE) no 726, 1901. ,
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis, Cochrane Database Syst Rev, 2014. ,
Palivizumab immunoprophylaxis: use in clinical practice, safety and beneficial effects in France. Arch Pédiatrie Organe Off Sociéte Fr Pédiatrie, 2009. ,
Respiratory syncytial virus and recurrent wheeze, N Engl J Med, 2013. ,
Rhône Alpes -Dieppe ,
Ile de France. -CH Lariboisière Paris Ile de France. -Blanc mesnil, Seine Saint Denis ,